|
BP13349
|
MKC3946
|
|
|
|
|
MKC3946 is an effective and soluble IRE1α inhibitor which triggered modest growth inhibition in multiple myeloma cell lines.
|
|
BP13350
|
MKC9989
|
|
|
|
|
MKC9989 is an inhibitor of Hydroxy aryl aldehydes (HAA). MKC9989 also inhibits IRE1α with an IC50 of 0.23 to 44 μM.
|
|
BP13351
|
ML-099
|
|
|
|
|
ML-099 is a pan Ras-related GTPases activator that activates Rac1, Ras, GTP-binding protein (Rab7), Rab2A and cell division cycle 42.
|
|
BP13352
|
ML141
|
|
|
|
|
ML141 is an effective, specific and reversible non-competitive inhibitor of Rho family GTPase cdc42 (IC50: 200 nM).
|
|
BP13353
|
ML167
|
|
|
|
|
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor.
|
|
BP13354
|
ML216
|
|
|
|
|
ML-216 is a small molecule inhibitor of BLM helicase (IC50: 1.8 μM). It showed 28-fold selective against the related helicases RECQ1, RECQ5, and E. coli UvrD (IC50s > 50 μM).
|
|
BP13355
|
ML264
|
|
|
|
|
ML264 is a selective kruppel-like factor 5 (KLF5) inhibitor, which potently Inhibits growth of Colorectal Cancer.
|
|
BP13356
|
ML-323
|
|
|
|
|
ML323 is a reversible and effective USP1-UAF1 inhibitor in a Ub-Rho assay (IC50: 76 nM) and in orthogonal gel-based assays using K63-linked diubiquitin (di-Ub) (IC50: 174 nM 820 nM)and monoubiquitinated PCNA (Ub-PCNA) (IC50: 820 nM) as substrates, respectively.
|
|
BP13357
|
ML364
|
|
|
|
|
ML364 is an inhibitor of ubiquitin specific peptidase 2 (USP2) and can be used for the research of breast cancer.
|
|
BP13358
|
ML-60218
|
|
|
|
|
ML-60218 is an inhibitor of broad-spectrum RNA pol III with IC50s of 32 and 27 μM for Saccharomyces cerevisiae and human. ML-60218 disrupts already assembled viroplasms and hampers the formation of new viroplasms.
|
|
BP13359
|
ML-7 hydrochloride
|
|
|
|
|
ML-7 Hcl is a cell-permeable, reversible, effective, ATP-competitive, and specific inhibitor of myosin light chain kinase (Ki: 300 nM); also inhibits smooth-muscle myosin light chain kinase, PKA, and PKC.
|
|
BP13360
|
MLCK inhibitor peptide 18 acetate
|
|
|
|
|
MLCK inhibitor peptide 18 acetate is a selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.
|
|
BP13361
|
MLN0905
|
|
|
|
|
MLN0905 is an effective PLK1 inhibitor(IC50=2 nM).
|
|
BP13362
|
MLS000532223
|
|
|
|
|
MLS000532223 is a selectiveRho family GTPases inhibitor(EC50 : 16 μM to 120 μM).
|
|
BP13363
|
MLS-573151
|
|
|
|
|
MLS-573151 is a selective inhibitor of GTPase Cdc42(EC50 of 2 μM). It is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type. MLS-573151 acts by blocking the binding of GTP to Cdc42.
|
|
BP13364
|
MM41
|
|
|
|
|
MM41 is a human telomeric and gene promoter DNA quadruplex stabilizer with an IC50 of <10 nM against the MIA PaCa-2 pancreatic cancer cell line.
|
|
BP13365
|
Moracin T
|
|
|
|
|
Moracin treatment can inhibit the double 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment-induced morphological changes reflecting inflammatory response, including leucocyte infiltration, hyperplasia and cell proliferation; moracin treatment furthermore can significantly suppress the elevation in 4-HNE level and elevate expression of c-fos, c-myc and cycloxygenase-2 (COX-2) in normal epidermis induced by double application of TPA; the moracin may be protective influence in tumor promotion, utilization of Moracin may open a new avenue in the treatment of tumerigenesis.
|
|
BP13366
|
MSC2530818
|
|
|
|
|
MSC2530818 is an effective, selective and orally available CDK8 inhibitor (IC50: 2.6 nM).
|
|
BP13367
|
Mupirocin
|
|
|
|
|
Mupirocin is a RNA synthetase inhibitor antibacterial. It has shown excellent activity against gram-positive staphylococci and streptococci.
|
|
BP13368
|
MYCi361
|
|
|
|
|
MYCi361 is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).
|
